Table of Contents
ISRN Ophthalmology
Volume 2012 (2012), Article ID 480212, 9 pages
http://dx.doi.org/10.5402/2012/480212
Review Article

Today and Future of Age-Related Macular Degeneration

Department of Ophthalmology, Kunming General Hospital of PLA, Yunnan, Kunming 650038, China

Received 27 December 2011; Accepted 29 January 2012

Academic Editors: H. Ahmadieh, B. Bui, A. Kakehashi, and W. H. Seiple

Copyright © 2012 Kang Liu and Bolin Xie. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 in developed countries. Understanding of the pathologic process, genetic mechanisms, and risk factors of this disease has the benefit of seeking newer and more effective treatment options. Current clinical therapy for AMD shows a dramatic change from a decade ago. Anti-VEGF drug therapy is regarded as the more effective treatment for neovascular AMD now, especially combining PDT therapy. In the future, the genetic and biochemical therapies may be the promising treatments for AMD. This paper will focus on the progress of pathology, candidate genes of AMD, risk factors, and the existing drugs or surgical therapies available, in order to present some new directions of care with the prospect of improved vision in many patients suffered from AMD.